[go: up one dir, main page]

MX2017007740A - Peptido c-terminal de acetilcolinesterasa ciclico en el tratamiento o la prevencion de cancer o metastasis. - Google Patents

Peptido c-terminal de acetilcolinesterasa ciclico en el tratamiento o la prevencion de cancer o metastasis.

Info

Publication number
MX2017007740A
MX2017007740A MX2017007740A MX2017007740A MX2017007740A MX 2017007740 A MX2017007740 A MX 2017007740A MX 2017007740 A MX2017007740 A MX 2017007740A MX 2017007740 A MX2017007740 A MX 2017007740A MX 2017007740 A MX2017007740 A MX 2017007740A
Authority
MX
Mexico
Prior art keywords
acetylcholinesterase
cyclic
cancer
metastasis
prevention
Prior art date
Application number
MX2017007740A
Other languages
English (en)
Other versions
MX376994B (es
Inventor
Adele Greenfield Susan
Pepper Christopher
Original Assignee
Neuro-Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuro-Bio Ltd filed Critical Neuro-Bio Ltd
Priority claimed from PCT/GB2015/054068 external-priority patent/WO2016097753A1/en
Publication of MX2017007740A publication Critical patent/MX2017007740A/es
Publication of MX376994B publication Critical patent/MX376994B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007—Acetylcholinesterase (3.1.1.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a polipéptidos cíclicos que derivan del C-terminal de la acetilcolinesterasa para el uso en el tratamiento o prevención del cáncer o la enfermedad metastásica.
MX2017007740A 2014-12-19 2015-12-18 Péptido c-terminal de acetilcolinesterasa cíclico para usarse en el tratamiento o la prevención de cáncer o metástasis. MX376994B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201422715 2014-12-19
GB1508480.9A GB2538947A (en) 2014-12-19 2015-05-18 Cancer
PCT/GB2015/054068 WO2016097753A1 (en) 2014-12-19 2015-12-18 Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis

Publications (2)

Publication Number Publication Date
MX2017007740A true MX2017007740A (es) 2017-09-05
MX376994B MX376994B (es) 2025-03-07

Family

ID=53505934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007740A MX376994B (es) 2014-12-19 2015-12-18 Péptido c-terminal de acetilcolinesterasa cíclico para usarse en el tratamiento o la prevención de cáncer o metástasis.

Country Status (15)

Country Link
US (2) US10441638B2 (es)
EP (2) EP3233110B1 (es)
JP (1) JP7066409B2 (es)
KR (1) KR102652620B1 (es)
CN (1) CN107106643B (es)
AU (1) AU2015365606B2 (es)
CA (1) CA2969990A1 (es)
DK (1) DK3233110T3 (es)
ES (1) ES2739543T3 (es)
GB (1) GB2538947A (es)
HU (1) HUE046299T2 (es)
MX (1) MX376994B (es)
PL (1) PL3233110T3 (es)
RU (1) RU2711161C2 (es)
SI (1) SI3233110T1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2538947A (en) * 2014-12-19 2016-12-07 Neuro-Bio Ltd Cancer
GB2546773B (en) * 2016-01-28 2020-06-17 Neuro Bio Ltd Cancer
GB202004803D0 (en) * 2020-04-01 2020-05-13 Neuro Bio Ltd Skin

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606040D0 (en) 1996-03-22 1996-05-22 Isis Innovation Active peptide
WO1998002452A2 (en) * 1996-07-12 1998-01-22 Mcgill University Compounds and methods for modulating cell adhesion
US20040204348A1 (en) 1996-11-12 2004-10-14 The Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US5958970A (en) * 1997-03-07 1999-09-28 Kansas State University Research Foundation Tricyclic and tetracyclic pyrones
IL131707A0 (en) * 1999-05-31 2001-03-19 Yissum Res Dev Co Acetylcholinesterase-derived peptides and uses thereof
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
AU2003302237A1 (en) * 2002-12-06 2004-06-30 Adaptive Therapeutics, Inc. Novel cyclic peptides comprising alpha-, beta- and gamma- amino acids
US20090169520A1 (en) * 2004-01-09 2009-07-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, Pharmaceutical Compositions and Therapeutic Methods of Preventing and Treating Diseases and Disorders Associated With Amyloid Fibril Formation
WO2007049281A1 (en) * 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ache polypeptides, polynucleotides encoding same and compositions and methods of using same
CA2803113A1 (en) * 2010-06-28 2012-01-12 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
EP2446893A1 (en) * 2010-11-01 2012-05-02 Bergen Teknologioverføring AS Use of nontoxic cyclic peptides to block transport via OATP1B1/ OATP1B3-related proteins, for the treatment of cancer cells expressing such transporters
CN102921000B (zh) * 2011-08-08 2015-02-18 中国科学院上海生命科学研究院 乙酰胆碱酯酶作为核酸酶的应用
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
GB2516045A (en) * 2013-07-09 2015-01-14 Neuro Bio Ltd Neurodegenerative disorders
GB2538947A (en) * 2014-12-19 2016-12-07 Neuro-Bio Ltd Cancer

Also Published As

Publication number Publication date
US20170368151A1 (en) 2017-12-28
BR112017012896A2 (en) 2018-02-06
EP3233110A1 (en) 2017-10-25
JP2018503609A (ja) 2018-02-08
KR20170113537A (ko) 2017-10-12
KR102652620B1 (ko) 2024-03-28
US20200147183A1 (en) 2020-05-14
PL3233110T3 (pl) 2019-11-29
CN107106643B (zh) 2021-12-07
DK3233110T3 (da) 2019-08-05
GB2538947A (en) 2016-12-07
MX376994B (es) 2025-03-07
US10441638B2 (en) 2019-10-15
AU2015365606A1 (en) 2017-06-29
RU2017120535A (ru) 2019-01-21
AU2015365606B2 (en) 2021-09-30
GB201508480D0 (en) 2015-07-01
HUE046299T2 (hu) 2020-02-28
EP3613428A1 (en) 2020-02-26
SI3233110T1 (sl) 2019-11-29
ES2739543T3 (es) 2020-01-31
CA2969990A1 (en) 2016-06-23
US11033609B2 (en) 2021-06-15
CN107106643A (zh) 2017-08-29
JP7066409B2 (ja) 2022-05-13
EP3233110B1 (en) 2019-05-01
RU2711161C2 (ru) 2020-01-15
RU2017120535A3 (es) 2019-06-19

Similar Documents

Publication Publication Date Title
PH12015501983B1 (en) Peptides and compositions for treatment of joint damage
ZA201708265B (en) Tigit-binding agents and uses thereof
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
MX2020010530A (es) Anticuerpos humanizados contra cd269 (bcma).
GEP20217331B (en) Anti-tigit antibodies
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2019000346A (es) Metodos y composiciones para el tratamiento del cancer.
JO3607B1 (ar) مضادات الأجسام المضادة لإنترفيرون ألفا وأوميجا
PH12017500853B1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
PH12017501549A1 (en) Peptides for inhibiting angiogenesis
EA201790990A1 (ru) Мультипептидный т-специфичный иммунотерапевтический препарат для лечения метастазов рака в головном мозге
MX2017007740A (es) Peptido c-terminal de acetilcolinesterasa ciclico en el tratamiento o la prevencion de cancer o metastasis.
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
EP3628048A4 (en) PEPTIDES FOR CANCER TREATMENT
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
EP3442559C0 (en) BMP-7 DERIVED PEPTIDES FOR USE IN THE TREATMENT OR PREVENTION OF OSTEOARTHRITIS
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
LT3626731T (lt) Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį
MX378112B (es) Anticuerpos que potencian el factor h y sus usos.
EA201691846A1 (ru) Композиции и способы лечения рака печени
MX2016006460A (es) Uso del peptido gk-1 como un agente anti-tumoral y/o anti-metastasico.
MX2019003002A (es) Terapias de combinacion que usan derivados de indazolilbenzamida para el tratamiento del cancer.
MX2018013863A (es) Terapias combinadas que usan derivados de indazolilbenzamida para el tratamiento del cancer.
GB2546703A (en) Compounds

Legal Events

Date Code Title Description
FG Grant or registration